Handelsbanken Fonder AB Increases Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Handelsbanken Fonder AB increased its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 930.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 246,069 shares of the biopharmaceutical company’s stock after buying an additional 222,200 shares during the period. Handelsbanken Fonder AB’s holdings in Halozyme Therapeutics were worth $9,095,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in HALO. Allspring Global Investments Holdings LLC increased its stake in Halozyme Therapeutics by 174.5% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 887,274 shares of the biopharmaceutical company’s stock worth $33,894,000 after buying an additional 563,989 shares during the period. Adage Capital Partners GP L.L.C. purchased a new stake in Halozyme Therapeutics during the 3rd quarter worth approximately $15,280,000. Federated Hermes Inc. grew its holdings in Halozyme Therapeutics by 176.0% during the 4th quarter. Federated Hermes Inc. now owns 459,369 shares of the biopharmaceutical company’s stock worth $16,978,000 after acquiring an additional 292,926 shares in the last quarter. Artisan Partners Limited Partnership grew its holdings in Halozyme Therapeutics by 3.4% during the 3rd quarter. Artisan Partners Limited Partnership now owns 7,712,874 shares of the biopharmaceutical company’s stock worth $294,632,000 after acquiring an additional 253,363 shares in the last quarter. Finally, Harvey Capital Management Inc. acquired a new position in Halozyme Therapeutics during the 4th quarter worth approximately $5,918,000. 97.79% of the stock is owned by hedge funds and other institutional investors.

Halozyme Therapeutics Stock Up 0.4 %

Shares of Halozyme Therapeutics stock opened at $39.12 on Thursday. The company has a market cap of $4.97 billion, a P/E ratio of 18.54, a PEG ratio of 0.45 and a beta of 1.25. The company has a debt-to-equity ratio of 17.89, a quick ratio of 5.50 and a current ratio of 6.64. Halozyme Therapeutics, Inc. has a one year low of $29.85 and a one year high of $45.00. The firm has a fifty day moving average of $39.71 and a two-hundred day moving average of $37.79.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). The company had revenue of $230.04 million during the quarter, compared to analysts’ expectations of $235.25 million. Halozyme Therapeutics had a net margin of 33.96% and a return on equity of 248.20%. On average, analysts forecast that Halozyme Therapeutics, Inc. will post 3.45 earnings per share for the current year.

Insider Activity

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $39.55, for a total transaction of $395,500.00. Following the completion of the transaction, the senior vice president now directly owns 156,558 shares in the company, valued at approximately $6,191,868.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold 30,000 shares of company stock worth $1,196,800 in the last 90 days. 2.40% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

HALO has been the subject of several analyst reports. The Goldman Sachs Group lowered their price target on shares of Halozyme Therapeutics from $45.00 to $40.00 and set a “neutral” rating for the company in a report on Thursday, January 18th. TD Cowen assumed coverage on shares of Halozyme Therapeutics in a report on Thursday, February 29th. They issued an “outperform” rating and a $54.00 target price for the company. TheStreet cut shares of Halozyme Therapeutics from a “b-” rating to a “c+” rating in a report on Monday, January 22nd. Benchmark restated a “buy” rating and issued a $50.00 target price on shares of Halozyme Therapeutics in a report on Tuesday, April 16th. Finally, StockNews.com upgraded shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, February 23rd. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $53.29.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.